miRNAs Can Affect Intestinal Epithelial Barrier in Inflammatory Bowel Disease

The most obvious pathological characterization of inflammatory bowel disease (IBD) is intestinal epithelium erosion and severe inflammation invasion. Micro-ribonucleic acids (miRNA or microRNA), single-stranded noncoding RNAs of ~22 nucleotides, have been considered as the potential therapeutic targ...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in immunology Jg. 13; S. 868229
Hauptverfasser: Xiao, Xiangjun, Mao, Xiangbing, Chen, Daiwen, Yu, Bing, He, Jun, Yan, Hui, Wang, Jianping
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Switzerland Frontiers Media S.A 13.04.2022
Schlagworte:
gene targets
Humans
Immunology
Inflammation - metabolism
inflammatory bowel disease
Inflammatory Bowel Diseases
intestinal epithelial barrier
Intestinal Mucosa - metabolism
Intestines - pathology
MicroRNAs - metabolism
miRNA
signaling pathways
gene targets
intestinal epithelial barrier
miRNA
signaling pathways
inflammatory bowel disease
ISSN:1664-3224, 1664-3224
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The most obvious pathological characterization of inflammatory bowel disease (IBD) is intestinal epithelium erosion and severe inflammation invasion. Micro-ribonucleic acids (miRNA or microRNA), single-stranded noncoding RNAs of ~22 nucleotides, have been considered as the potential therapeutic targets in the pathogenesis of IBD. Many previous studies have focused on the mechanisms that miRNAs use to regulate inflammation, immunity, and microorganisms in IBD. The review highlights in detail the findings of miRNAs in the intestinal epithelial barrier of IBD, and focuses on their gene targets, signaling pathways associated with IBD, and some potential therapies. It will be beneficial for the elucidation of the interaction between miRNAs and the intestinal epithelial barrier in IBD and provide a theoretical reference for preventing and treating IBD in the future.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Nivedita Banerjee Chakrabarty, University of Texas Medical Branch at Galveston, United States; Hongbing Guan, Guangzhou Medical University, China; Maria Gazouli, National and Kapodistrian University of Athens, Greece; Eun Jeong Park, Mie University, Japan
These authors have contributed equally to this work
Edited by: Tanima Bose, Ludwig Maximilian University of Munich, Germany
This article was submitted to Mucosal Immunity, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.868229